# CheckMate 8HW (NCT04008030)

> A Study of Nivolumab, Nivolumab Plus Ipilimumab, or Investigator's Choice Chemotherapy for the Treatment of Participants With Deficient Mismatch Repair (dMMR)/Microsatellite Instability High (MSI-H) Metastatic Colorectal Cancer (mCRC)

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT04008030
- Phase: PHASE3
- Status: ACTIVE_NOT_RECRUITING
- Sponsor: Bristol-Myers Squibb
- Conditions: Metastatic Colorectal Cancer
- Interventions: Ipilimumab; Oxaliplatin; Leucovorin; Fluorouracil; Irinotecan; Bevacizumab; Cetuximab; Nivolumab
- Enrollment: 839
- Primary outcome: Progression-free Survival (PFS) by Blinded Independent Review Center (BICR) - Arm B vs. Arm A All Lines Centrally Confirmed MSI-H/dMMR
- Primary outcome: Progression-free Survival (PFS) by Blinded Independent Review Center (BICR) - Arm B vs. Arm C 1L Participants Centrally Confirmed MSI-H/dMMR

## Commentary we found

- X threads: 106
- YouTube: 80
- Podcasts: 49
- X videos: 1

## Order

Deep, $1,950, price fixed at order: https://www.erudio.com/contact?report=checkmate-8hw-nct04008030

## Free build

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT04008030", "email": "<work email>"}; the inbox owner confirms by the emailed link.